From the HBV Cure Workshop to AASLD The Liver Meeting 2026, PBGENE-HBV took the stage in Denver!
At AASLD The Liver Meeting® 2026, ELIMINATE-B lead investigator Man Fung Yuen, MD, PhD, Chair Professor of The University of Hong Kong and Chief of the Division of Gastroenterology and Hepatology, Queen Mary Hospital, delivered a late-breaking oral presentation featuring new and updated data from 25 patients across 59 administrations in the Phase 1 ELIMINATE-B trial.
At the expected go-forward dose of 0.4 mg/kg, PBGENE-HBV achieved pgRNA loss to undetectable in 100% of evaluable patients.
Emily B. Harrison, PhD, Director of Translational Sciences, also presented PBGENE-HBV data at the HBV Cure Workshop in Denver.
PBGENE-HBV is the first and only in vivo gene editing therapy designed to eliminate the root cause of chronic hepatitis B, covalently closed circular DNA (cccDNA), to drive viral cure measured by sustained undetectable HBV DNA.
Read the full release, loom.ly/MZYmQqI
#PrecisionBioSciences #DTIL #HepatitisB #AASLD
At AASLD The Liver Meeting® 2026, ELIMINATE-B lead investigator Man Fung Yuen, MD, PhD, Chair Professor of The University of Hong Kong and Chief of the Division of Gastroenterology and Hepatology, Queen Mary Hospital, delivered a late-breaking oral presentation featuring new and updated data from 25 patients across 59 administrations in the Phase 1 ELIMINATE-B trial.
At the expected go-forward dose of 0.4 mg/kg, PBGENE-HBV achieved pgRNA loss to undetectable in 100% of evaluable patients.
Emily B. Harrison, PhD, Director of Translational Sciences, also presented PBGENE-HBV data at the HBV Cure Workshop in Denver.
PBGENE-HBV is the first and only in vivo gene editing therapy designed to eliminate the root cause of chronic hepatitis B, covalently closed circular DNA (cccDNA), to drive viral cure measured by sustained undetectable HBV DNA.
Read the full release, loom.ly/MZYmQqI
#PrecisionBioSciences #DTIL #HepatitisB #AASLD